Molecular pathways in the formation of gliomas

Glia

Volumn 15, Issue 3, 1995, Pages 328-338

  von Deimling, Andreas ^a   Louis, David N ^b   Wiestler, Otmar D ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Astrocytoma; Glioblastoma multiforme; Loss of heterozygosity; Molecular classification; Molecular genetics; Oligodendroglioma; Oncogenes; Tumor suppressor genes

Indexed keywords

ASTROCYTOMA; BRAIN TUMOR; GENE DELETION; GENETICS; GLIOBLASTOMA; GLIOMA; HUMAN; METABOLISM; MUTATION; OLIGODENDROGLIOMA; PATHOLOGY; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; GENE DELETION; GENES, ERBB-1; GENES, P53; GLIOBLASTOMA; GLIOMA; HUMANS; MUTATION; OLIGODENDROGLIOMA;

EID: 0029397626     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.440150312     Document Type: Article

References (58)

1. p53 mutations occur in combination with 17p allele deletions as late events in colorectal tumorigenesis
2. Gene amplification in malignant human gliomas: Clinical and histopathologic aspects
3. Specific chromosomal abnormalities in malignant human gliomas
4. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
5. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
6. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Reckling‐hausen (type 1) neurofibromatosis
7. Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas
8. Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma
9. Allelotype of human malignant astrocytoma
10. Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors
11. Tumors of the orbit, optic nerve and lacrimal sac
12. Regulation of ras‐GAP and the neurofibromatosis 1 gene product by eicosanoids
13. The retinoblastoma gene is involved in malignant progression of astrocytomas
14. p53 mutations in human cancers
15. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
16. Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis
17. Clonal genomic alterations in glioma malignancy stages
18. Mitotic recombination of chromosome 17 in astrocytomas
19. Loss of genetic information in central nervous system tumors common to children and young adults
20. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta‐1 gene deletions in human glial tumors
21. Deletion of p16 and p15 genes in brain tumors
22. A cell cycle regulator potentially involved in genesis of many tumors
23. Mutation and cancer: Statistical study of retinoblastoma
24. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
25. Von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata
26. Somatic mutations in the neurofibromatosis 1 gene in human tumors
27. Amplification, enhanced expression and possible rearrangement of EGF receptor in primary human brain tumors of glial origin
28. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens
29. Mutations in the p53 gene occur in diverse tumor types
30. Loss of p16INK4 expression is frequent in high grade gliomas
31. Deletions of the cyclin‐dependent kinase‐4 inhibitor gene in multiple human cancers
32. p53 mutations in nonastrocytic human brain tumors
33. Amplification of a gene encoding a p53 associated protein in human sarcomas
34. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers
35. Cytogenetic and loss of heterozygosity studies in ependymoma, pilocytic astrocytoma and oligodendrogliomas
36. Amplification of multiple genes from chromosomal region 12q13‐q14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS and MDM2
37. The putative glioma suppressor gene on chromosome 19q maps between APOC2 and HRC
38. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
39. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma
40. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene
41. A small deletion and an adjacent base exchange in a potential stem‐loop region of the neurofibromatosis 1 gene
42. MTS1 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p
43. Retinoblastoma gene deletions in human glioblastomas
44. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
45. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma
46. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
47. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas and mixed gliomas
48. A rapid and nonradioactive PCR based assay for the detection of allelic loss in human gliomas
49. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma
50. Subsets of glioblastoma multiforme defined by molecular genetic analysis
51. Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q
52. Deletion mapping of a putative tumor suppressor gene on chromosome 19q associated with human gliomas
53. Neurofibromatosis type 1: Pathology, clinical features and molecular genetics
54. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients
55. Supratentorial anaplastic gliomas in adults
56. The neurofibromatosis type 1 gene encodes a protein related to GAP